First AD

Second AD

Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

Please comment on the risk stratification tools IPSS-M and if you have adapted using this stratification tool in your practice.

What do you are share to your patients in terms of prognosis for those with lower-risk MDS?

What are some current challenges for treating lower-risk MDS?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice

Panelists discuss how risk stratification tools like IPSS-M are applied in practice for lower-risk myelodysplastic syndromes, addressing prognosis communication and current treatment challenges for this patient group.